 |
 |
肿瘤科论文CerbB2在乳腺癌中的表达意义
【摘要】 目的 探讨C erbB2在乳腺癌中的表达意义。方法 采用免疫组化SP法检测161例乳腺浸润性导管癌中CerbB2的表达。结果 CerbB2在＜50岁与≥50岁年龄组表达率分别为27.43%和31.25%，差异无统计学意义(P＞0.05)；在浸润性导管癌Ⅰ、Ⅱ、Ⅲ级中表达率分别为19.05%、24.21%、42.22%，在Ⅰ、Ⅱ级中明显低于Ⅲ级中(P＜0.05)；在淋巴结无转移组、低转移组表达率分别为20.43%、29.41%，明显低于高转移组44.0%(P＜0.05)。结论 CerbB2的表达与乳腺癌的组织学分级高，淋巴结高转移率密切相关。CerbB2的检测可作为乳腺癌预后判断的重要参考指标。
【关键词】 乳腺浸润性导管癌；免疫组织化学；CerbB2；癌基因 The expression of CerbB2 in Peast invasive ductal carcinoma WANG Chunyang, HU Jiangong*,SHAO Xuezhai，et al. Department of Pathology, Affiliated Hospital of Chengde Medical college,Hebei,Chengde 067000,China
【Abstract】Objective To investigate the significance of expression of C erbB2 in Peast carcinoma.Methods The expression of CerbB2 was detected by SP immunohistochemical technique in 161 cases of Peast invasive ductal carcinoma.Results The expressing rates of CerbB2 were 27.43% and 31.25% in the age group above 50 and below 50 years respectively, and there was no significant difference between the two age groups(P＞0.05). The positive expressing rates of CerbB2 were 19.05%, 24.21% and 42.22% in Peast carcinoma tissues at grade 1, 2 and 3 respectively,which was higher in grade 3 than that in other two groups (P<0.05). CerbB2 expressing rates in patients without and with low frequency of lymph node metastases were 20.43%, 29.41% respectively,which was significantly higher than that (44.0%) in high frequency of lymph node metastases (P<0.05).Conclusion The overexpression of CerbB2 was closely related with a high histological grade and high frequency of lymph node metastases.CerbB2 may be a valuable prognostic indicator for Peast invasive ductal carcinoma.
【Key words】Peast invasive ductal carcinoma； immunohistochemistry； CerbB2; oncogene 乳腺癌是女性最常见的恶性肿瘤之一，在西方国家其发病率和病死率均居女性恶性肿瘤之首。我国女性乳腺癌的发病率亦不断上升,且有年轻化趋势。组织学分级高、临床分期高和有淋巴结转移是公认的预后不良指标。近年来随着分子生物学的不断发展，乳腺癌的分子预后指标越来越受到人们的关注。CerbB2是一种重要的癌基因，其产物过度表达与肿瘤恶性程度高、生长快、预后差密切相关［1］。为探讨CerbB2在乳腺癌的表达意义，本研究采用免疫组化方法检测乳腺浸润性导管癌组织中CerbB2的表达医学全.在线www.med126.com。
1 资料与方法
1.1 一般资料 标本均为我院2005至2006年乳腺浸润性导管癌简化根治手术标本。患者全部为女性，共161例，年龄26～78岁，平均年龄48.6岁；＜50岁113例，≥50岁48例；其中Ⅰ级21例，Ⅱ级95例，Ⅲ级45例；无淋巴结转移93例，淋巴结转移＜3枚17例，≥3枚51例。病理诊断参照WHO《乳腺及女性生殖器官肿瘤病理学和遗传学(2003)》进行分类。 1.2 试剂 CerbB2单克降抗体、SP免疫组化染色试剂盒、DAB显色试剂盒均购自福州迈新生物技术公司。 1.3 方法 标本均经10%中性甲醛固定，5 μm连续切片，每例2片，1片做HE染色复核病理诊断，另1片检测CerbB2的表达。石蜡切片常规脱蜡入水；加3%H2O2溶液50 μl阻断过氧化物酶；加热修复抗原20 min；加10%正常山羊血清封闭，室温孵育10 min，加一抗(1∶50稀释)；4℃过夜；加生物素标记的二抗，37℃孵育30 min；加辣根酶标记的链霉卵白素溶液，37℃孵育30 min；DAB显色。以上各步骤间均用PBS缓冲液漂洗3次，每次5 min。苏木素复染，脱水，透明，封片，镜下观察。 1.4 判断标准 结果判断采用美国FDA新判断标准：CerbB2 阳性部位在细胞膜，细胞膜出现连续的棕黄色颗粒，且着色细胞数＞30%为阳性着色。 1.5 统计学分析 计数资料采用χ2检验，P＜0.05为差异有统计学意义。
